Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Adipose-Derived Mesenchymal Stem Cells Improve Motor Function and Reduce Neuroinflammation and Mutant Ataxin-3 Protein Levels in SCA3 Mice.

International journal of stem cells·2026
Same author

Advanced therapies require soft skills: insights from a National Academies Working Group.

Cytotherapy·2026
Same author

Proceedings of the ISCT scientific signature series symposium, "Advances in cell and gene therapies for lung diseases and critical illnesses": International Society for Cell & Gene Therapy, Burlington VT, US, July 16, 2021.

Cytotherapy·2022
Same author

Augmented Expansion of Treg Cells From Healthy and Autoimmune Subjects <i>via</i> Adult Progenitor Cell Co-Culture.

Frontiers in immunology·2021
Same author

IFN-γ and PPARδ influence the efficacy and retention of multipotent adult progenitor cells in graft vs host disease.

Stem cells translational medicine·2021
Same author

Multipotent adult progenitor cells induce regulatory T cells and promote their suppressive phenotype via TGFβ and monocyte-dependent mechanisms.

Scientific reports·2021
Same journal

Introduction to pediatric solid organ transplantation - not just little adults!

Current opinion in organ transplantation·2026
Same journal

Editorial introduction.

Current opinion in organ transplantation·2026
Same journal

Precision medicine guided development of new immunosuppression strategies in solid organ transplantation.

Current opinion in organ transplantation·2026
Same journal

Intestinal transplantation for tumors.

Current opinion in organ transplantation·2026
Same journal

Current state of medical rehabilitation for adult short bowel syndrome patients with intestinal failure.

Current opinion in organ transplantation·2026
Same journal

Update on costimulatory blockade in transplantation: a review of recent literature.

Current opinion in organ transplantation·2026
See all related articles

Related Experiment Video

Updated: May 17, 2026

Delayed Intramyocardial Delivery of Stem Cells after Ischemia Reperfusion Injury in a Murine Model
07:50

Delayed Intramyocardial Delivery of Stem Cells after Ischemia Reperfusion Injury in a Murine Model

Published on: September 3, 2020

Allogeneic stem cell transplantation for ischemic myocardial dysfunction.

Anthony E Ting1, Warren Sherman

  • 1Athersys Inc., Cleveland, Ohio 44115, USA. ating@athersys.com

Current Opinion in Organ Transplantation
|November 1, 2012
PubMed
Summary
This summary is machine-generated.

Stem cell therapy shows promise for cardiovascular disease treatment, utilizing various cell types and delivery methods. Allogeneic stem cells offer potential for off-the-shelf use in ischemic heart disease without immunosuppression.

More Related Videos

Ultrasound-Guided Induced Pluripotent Stem Cell-Derived Cardiomyocyte Implantation in Myocardial Infarcted Mice
08:03

Ultrasound-Guided Induced Pluripotent Stem Cell-Derived Cardiomyocyte Implantation in Myocardial Infarcted Mice

Published on: March 30, 2022

Intramyocardial Transplantation of MSC-Loading Injectable Hydrogels after Myocardial Infarction in a Murine Model
09:19

Intramyocardial Transplantation of MSC-Loading Injectable Hydrogels after Myocardial Infarction in a Murine Model

Published on: September 20, 2020

Related Experiment Videos

Last Updated: May 17, 2026

Delayed Intramyocardial Delivery of Stem Cells after Ischemia Reperfusion Injury in a Murine Model
07:50

Delayed Intramyocardial Delivery of Stem Cells after Ischemia Reperfusion Injury in a Murine Model

Published on: September 3, 2020

Ultrasound-Guided Induced Pluripotent Stem Cell-Derived Cardiomyocyte Implantation in Myocardial Infarcted Mice
08:03

Ultrasound-Guided Induced Pluripotent Stem Cell-Derived Cardiomyocyte Implantation in Myocardial Infarcted Mice

Published on: March 30, 2022

Intramyocardial Transplantation of MSC-Loading Injectable Hydrogels after Myocardial Infarction in a Murine Model
09:19

Intramyocardial Transplantation of MSC-Loading Injectable Hydrogels after Myocardial Infarction in a Murine Model

Published on: September 20, 2020

Area of Science:

  • Regenerative Medicine
  • Cardiovascular Research
  • Stem Cell Biology

Background:

  • Cardiovascular disease remains a leading cause of mortality worldwide.
  • Current treatments for myocardial injury have limitations.
  • Stem cell therapy presents a promising avenue for cardiac repair.

Purpose of the Study:

  • To review the current state of stem cell therapy for cardiovascular disease.
  • To explore various cell populations, delivery methods, and administration timings.
  • To summarize recent findings and future directions in the field.

Main Methods:

  • Review of preclinical animal models of myocardial disease.
  • Analysis of clinical studies involving stem cell transplantation.
  • Investigation of mechanisms underlying stem cell-mediated cardiac repair.

Main Results:

  • Initial studies utilized unfractionated bone marrow cells.
  • Animal models elucidated mechanisms of benefit for various stem cell types.
  • Allogeneic stem cell populations demonstrated therapeutic potential.

Conclusions:

  • Allogeneic stem cells show promise for ischemic heart disease treatment.
  • No immunosuppressive drugs are required for allogeneic stem cell therapy.
  • Potential for large-scale, cryopreserved stem cell banks for clinical use.